Liberate Medical

Sep 7, 2023

Money will help finance the clinical trial of the company's VentFree Respiratory Muscle Stimulator. Michael Barbella, Managing Editor09.07.23 Liberate Medical  has closed a $6.2 million Series B financing round co-led by a large strategic investor and Scientific Health Development , both of which will both join the companyl’s Board of Directors. "We are thrilled to have Scientific Health Development and our strategic partner join us as co-leads in this Series B financing round," Liberate Medical CEO Angus McLachlan said. "Their support and expertise will be instrumental as we conduct the PREVENT trial and prepare for full commercialization of VentFree.” Liberate Medical’s VentFree Respiratory Muscle Stimulator is the only non-invasive, breath synchronized, neuromuscular electrical stimulator intended to prevent expiratory muscle atrophy in mechanically ventilated patients, according to Liberate Medical. A key focus of the funding will be to support the pivotal clinical trial of VentFree, known as the PREVENT trial. The PREVENT trial aims to demonstrate that VentFree reduces the duration of invasive mechanical ventilation in patients at risk of being difficult to wean. Reducing the time patients spend on mechanical ventilation may reduce the risks of prolonged mechanical ventilation, including hospital acquired infections, deteriorated quality of life and death. The Series B funding will provide the necessary resources to complete the PREVENT trial, in anticipation of U.S. Food and Drug Administration (FDA) regulatory clearance and VentFree's full commercial launch. The PREVENT study follows two successful pilot randomized controlled trials that were completed in Europe and Australia. VentFree has received FDA Breakthrough Device Designation, FDA Emergency Use Authorization, and CE marking in the European Union. “SHD is proud to support Angus and the Liberate Medical team,” Scientific Health Development CEO/General Partner Andrew Offer stated. “I am honored to join the Board of Directors and play a role in changing the standard of care for weaning mechanically ventilated patients. VentFree will improve quality of life for patients and their families.” Liberate Medical develops neuromuscular electrical stimulation technology to improve the quality and reduce the cost of care for patients with pulmonary disorders. Scientific Health Development is a Dallas-based venture capital firm focused on early-stage investments in high-impact medical device and diagnostics companies across various specialties. Formed in 2006, SHD is actively investing out of its fourth fund. Trending